PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) released its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.91 by ($1.15), FiscalAI reports. The business had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $30.00 million.

Here are the key takeaways from PolyPid’s conference call:

• FDA review is nearing a key decision: D-PLEX100’s priority-review PDUFA date is November 28, with labeling discussions underway and scheduled FDA interactions described as on track. Approval and the planned early-2027 launch remain subject to FDA action; the company did not discuss inspection details.
• PolyPid and Azurity are preparing for a U.S. launch, with Azurity building its commercial teams and targeting hospitals. The company cautioned that formulary reviews happen account by account and adoption may take several months; a CMS decision on NTAP reimbursement is expected in August 2027.
• Label expansion is a potential growth driver: PolyPid plans to begin FDA discussions this quarter on expanding D-PLEX100 beyond colorectal surgery to broader abdominal procedures. The company has not yet received FDA feedback on what evidence or requirements would be needed.
• The EMA validated PolyPid’s D-PLEX100 application and began its review, with a decision expected in the second half of 2027. After ending its European agreement with ADVANZ PHARMA, PolyPid regained commercialization rights and said it is discussing potential partnerships.
• PolyPid reported $15.5 million in cash and short-term deposits at quarter-end and said it received a further $15 million Azurity payment in early October; management expects resources to fund operations into 2028. The company also plans PD01B’s pre-IND meeting and first-in-human study in the second half of 2027, while the program remains in development.

PolyPid Price Performance

PYPD opened at $6.60 on Thursday. The company’s 50-day moving average is $5.32 and its 200 day moving average is $4.78. PolyPid has a fifty-two week low of $3.50 and a fifty-two week high of $7.15. The firm has a market capitalization of $125.95 million, a P/E ratio of -4.46 and a beta of 1.43.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of PolyPid in a report on Thursday. Craig Hallum set a $12.00 target price on shares of PolyPid in a report on Wednesday, July 22nd. Oppenheimer started coverage on shares of PolyPid in a research report on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a research note on Friday, September 18th. Finally, Wall Street Zen upgraded PolyPid from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, PolyPid presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

More PolyPid News

These are some of the PYPD news items that stood out recently:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $13 price target, implying substantial upside from the cited $6.60 share price. HC Wainwright rating information
• Positive Sentiment: D-PLEX₁₀₀ is under FDA priority review, with a November 28, 2026 PDUFA goal date. PolyPid says U.S. commercial-launch preparations are underway, making the pending decision a significant near-term catalyst. Company update and Q3 results
• Negative Sentiment: PolyPid reported a Q3 loss of $0.24 per share, missing the cited analyst consensus of $0.91 per share. Revenue was $30 million, in line with expectations; the earnings shortfall may temper optimism around the product launch. Q3 earnings report

About PolyPid

PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure. PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix. It is being developed for the prevention of surgical-site infections, initially in patients undergoing colorectal surgery.